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Abstract
Background: The first subjects with deficiency of mitochondrial tryptophanyl-tRNA synthetase (WARS2) were
reported in 2017. Their clinical characteristics can be subdivided into three phenotypes (neonatal phenotype, severe
infantile onset phenotype, Parkinson-like phenotype).
Results: Here, we report on a subject who presented with early developmental delay, motor weakness and intellectual
disability and who was considered during several years as having a non-progressive encephalopathy. At the age of six
years, she had an epileptic seizure which was treated with sodium valproate. In the months after treatment was started,
she developed acute liver failure and severe progressive encephalopathy. Although valproate was discontinued, she died
six months later. Spectrophotometric analysis of the oxidative phosphorylation complexes in liver revealed a deficient
activity of complex III and low normal activities of the complexes I and IV. Activity staining in the BN-PAGE gel confirmed
the low activities of complex I, III and IV and, in addition, showed the presence of a subcomplex of complex V.
Histochemically, a mosaic pattern was seen in hepatocytes after cytochrome c oxidase staining. Using Whole Exome
Sequencing two known pathogenic variants were detected in WARS2 (c.797delC, p.Pro266ArgfsTer10/ c.938 A > T, p.
Lys313Met).
Conclusion: This is the first report of severe hepatopathy in a subject with WARS2 deficiency. The hepatopathy occurred
soon after start of sodium valproate treatment. In the literature, valproate-induced hepatotoxicity was reported in the
subjects with pathogenic mutations in POLG and TWNK. This case report illustrates that the course of the disease in the
subjects with a mitochondrial defect can be non-progressive during several years. The subject reported here was first
diagnosed as having cerebral palsy. Only after a mitochondriotoxic medication was started, the disease became
progressive, and the diagnosis of a mitochondrial defect was made.
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Background
The oxidative phosphorylation (OXPHOS) system is em-
bedded in the inner mitochondrial membrane and consists
of five complexes. Thirteen subunits of the OXPHOS com-
plexes are encoded by mitochondrial DNA (mtDNA). A
series of nuclear-encoded proteins are needed to carry out
transcription and translation in the mitochondrial matrix.
The latter are synthesized in the cytosol and have to be
imported into the mitochondrial matrix. An important
group among these are the mitochondrial aminoacyl-tRNA
synthetases (mt-aaRSs) [1]. This is a well-described group
of enzymes responsible for charging the mitochondrial-
encoded tRNAs with their cognate amino acid. Defects in
mt-aaRSs result in defective intramitochondrial translation,
affecting mainly the OXPHOS complexes with the largest
number of mitochondrial-encoded subunits, i.e. complex I
and complex IV. The activity of complex II is normal, or
even upregulated, as it is exclusively composed of nuclear-
encoded subunits. The mitochondrial aaRSs differ from
their cytoplasmic counterparts except for the enzymes
encoded by GARS and KARS that take care of translation
in the cytoplasm and in the mitochondria [1, 2].
DARS2 was the first mt-aaRS to be associated with a hu-
man disease [3]. During the last decade, molecular alter-
ations in all nineteen mt-aaRSs have been linked to a
heterogeneous group of human disorders affecting different
organ systems. Mutations in a single gene can cause either
a mild or severe phenotype, or even result in completely
different phenotypes, as shown for AARS2, NARS2 and
FARS2 [4–6]. The first observation of WARS2 deficiency
has been reported by Musante et al. in 2017 [7]. WARS2
codes for tryptophanyl-tRNA synthetase active in the mito-
chondria [8]. Three more papers describing WARS2 defi-
cient subjects were published subsequently [9–11].
Here, we present a 6-year-old girl in whom severe delay
of early cognitive and motor development and mild dys-
morphic facial features were initially suggestive of cerebral
palsy or a chromosomal disorder as she was slightly dys-
morphic. Karyotyping and CGH-microarray were normal.
It was only after sodium valproate was initiated that acute
liver failure was diagnosed and the diagnosis of a mito-
chondrial disorder was suspected and confirmed.
Methods
Spectrophotometric analysis
Activity of citrate synthase and respiratory chain com-
plexes I, II, II + III, III and IV were measured in liver
homogenate using spectrophotometric analysis accord-
ing to previously described methods [12].
Blue native-polyacrylamide gel electrophoresis
Blue native polyacrylamide gel-electrophoresis (BN-PAGE)
was used to separate and assay the activity of the five
OXPHOS complexes. Mitochondria isolated from the
proband’s liver and from controls were loaded in duplicate
using equal amounts of mitochondrial protein (50 μg). Iso-
lation and solubilization of the complexes, separation by
BN-PAGE and staining of catalytic activities in the gel were
performed as described earlier [13].
Light microscopy, cytochemical analysis and electron
microscopy of liver
Liver tissue was obtained by laparoscopy. One part was
frozen for biochemical analysis and another part formalin-
fixed and paraffin embedded. Hematoxylin and eosin
staining and periodic acid-Schiff (PAS) staining before and
after diastase digestion of glycogen were performed,
as were stains of reticulin, immunostains using antibodies
for cytokeratin-7 and Ki67, iron staining and staining with
Sirius red.
For cytochrome c oxidase cytochemistry, liver tissue
was fixed in cold glutaraldehyde 1% for two hours. After
rinsing in saccharose 13%, frozen sections were stained
for cytochrome c oxidase activity with diaminobenzidine
at pH 6, as previously described [14]. Six µm sections
were mounted after nuclear staining with light green.
For electron microscopy, 60 μm sections were postfixed
in OsO4 and embedded in epoxy resin. Semithin sec-
tions were studied by light microscopy. Ultrathin sec-
tions were counterstained with lead and studied in a
Zeiss electron microscope.
Whole exome sequencing
Exome enrichment and sequencing were performed by
Aros AB (Aarhus, Denmark) using the Illumina TruSeq
Exome Enrichment Kit (Illumina, San Diego, CA),
followed by paired-end sequencing on a HiSeq 2000
(2 × 100 cycles). Data analysis including alignment to
the GRCh37 human reference genome (NCBI), variant
calling and variant filtering was done using the in-house
developed analysis pipeline Seqplorer.
Western blot analysis
Western blotting was performed using commercial anti-
bodies against WARS2 (Sigma AV52366), VDAC-1 (Abcam,
AB14734) and a cocktail of commercial antibodies directed
against one subunit in each of the five OXPHOS complexes
(NDUFB8 for complex I, SDHB for complex II, UQCRC2
for complex III, COX2 for complex IV and subunit alpha
for complex V) (MS601 MitoProfile® Total OXPHOS Hu-
man WB Antibody Cocktail). Detection was performed
using the ECL Plus™ enhanced chemiluminescence kit (GE
Healthcare, Diegem, Belgium), as described previously [15].
A chemidoc-It © 500 Image System, UVP (Cambridge, UK)
with a cooled charge-coupled device camera was used to
capture the WARS2 signals. Image processing was per-
formed using VisionWorksLQ image acquisition software.
Biostep Celvin® S420 chemiluminescence imager from
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Biostep Gmbh ® (Burkhardtsdorf, Germany) equipped with a
cooled charge-coupled device with a resolution of 4.2
Mpixel was used to capture the other signals. Image acquisi-
tion was achieved using the Celvin® SnapAndGo software
and TotalLab for image analysis.
Whole cell lysates and mitochondrial fractions were
prepared from skeletal muscle and heart muscle from
controls. The same fractions were prepared from liver
from the proband and controls. Electrophoretic separ-
ation was performed using tricine SDS-PAGE.
Results
Case report
The proband was born at term from non-consanguineous
parents. Antenatal ultrasound examination revealed intra-
uterine growth retardation. Birth weight was 2314 g,
length 45 cm and head circumference 31.8 cm. The neo-
natal period was without complications. When examined
at the age of eleven months, severe axial hypotonia, hyper-
tonia and dystonic posturing of arms and legs were no-
ticed and she was found to have slight dysmorphic
features, i.e. a thin upper lip, low set ears, a broad nasal
bridge, hypertelorism of the eyes and an ogival palatum.
Eye movements were complete. Pyramidal tract signs were
not found. Length was 67 cm (− 2.5 SD), weight 7.6 kg
(− 2 SD) and head circumference 45 cm (0 SD). Brain
MRI showed a relative small volume of both frontotem-
poral lobes, enlarged sulci and small zones with increased
signal bilaterally on T2 weighted images in the frontal
subcortical zones. When seen at eighteen months of age, a
severe delay of cognitive and motor development was con-
firmed. The cognitive development was estimated at less
than six months. She had no head control and rigidity of
arms and legs was noticed. Fists were bilaterally clenched.
Deep tendon reflexes were weak and both feet were in
equinus position. At six years of age, she was hospitalized
because of a long lasting episode with decreased aware-
ness, lateral eye deviation and twitching of the eyelids at
the left. Hypoglycemia and a slightly increased lactate
(which turned out to be normal on the next day) were de-
tected in serum on admission. Sodium valproate was
started. One month later, she was taken to a local hospital
after she was found stuporous at home in the morning.
Dystonic posturing of the limbs together with motor
hyperactivity and continuous choreatic movements were
seen. Deep tendon reflexes were present although weak.
Plantar reflexes were indifferent. Blood sugar concentra-
tion was 8 mg/dl (nl 60–130). In the course of two days,
SGOT rapidly increased from 188 IU/L to 1000 IU/L
(nl < 42) and SGPT from 159 to 487 IU/L (nl 5–25).
Gamma-glutamyltransferase was 232 IU/L (nl 4–22).
Concentration of sodium valproate in serum was 18 μg/ml
(nl 50–90). On the second day of hospitalization, lactate in
serum was high (5.5–12.8 mmol, nl < 1.8) and glycaemia
was normalized. Urinary organic acid profile showed high
concentrations of lactate (2686 μmol/mmol creatinine,
nl < 131), pyruvate (66 μmol/mmol creatinine, nl < 17),
3-OH-butyrate (3161 μmol/mmol creatinine, nl < 7)
and 3-keto-butyrate (2968 μmol/mmol creatinine, nl < 5).
Acylcarnitine profile was normal. In CSF, cell count was
not increased, glucose concentration was 66 mg/dl,
protein 10 mg/dl and lactate 2.8 mmol (nl < 1.7). Coagula-
tion parameters were perturbed (PT 34%, nl 70–120; aptt
51 s, nl 29–38), direct bilirubin was only slightly increased
(0.41 mg/dL, nl 0–0.3) and indirect bilirubin was normal.
Ammonemia was normal (34 μmol, nl 11–48). Sodium
valproate was stopped immediately and phenobarbital was
started. Ophthalmological examination revealed optic
atrophy. EEG and electroneuromyographic examination
were normal. Cerebral MRI showed enlargement of the
lateral ventricles and third ventricle presumably due to
white matter loss. Subarachnoidal spaces were abnormally
large, most marked in the frontal regions bilaterally. In the
posterior fossa, the vermis cerebelli was hypoplastic, the
fourth ventricle was enlarged and the brainstem and cere-
bellar peduncles were hypoplastic. No signs of periven-
tricular leucomalacia, neither of cystic encephalopathy
were seen. She was discharged from the hospital. One
month later, she was found stuporous and was referred
now to the University Hospital. On arrival, she was icteric
and the liver was borderline enlarged (1 cm below the
costal margin). Transaminases were severely increased in
serum (> 1000 IU/L). Coagulation parameters were per-
turbed. Direct bilirubin was 9 mg/dL and serum albumin
was decreased (2.8 g/dL). Ammonemia was normal
(36 μmol/L, nl 11–48). Lactate was 66 mg/dL (nl 9–16).
She was diagnosed with acute liver failure (ALF) and
metabolic encephalopathy. The urinary organic acid
profile was suggestive for a defect in the oxidative phos-
phorylation. Plasma amino acid profile showed a slight
increase of alanine, tyrosine and phenylalanine. In CSF,
the lactate concentration was 2.8 mmol (nl < 1.8) and glu-
cose 66 mg/dL (concomitant serum glucose 82 mg/dL).
Echocardiogram was normal. Ultrasound examination of
the liver showed increased reflectivity. She was discharged
from hospital and a treatment was prescribed consisting
of levetiracetam (380 mg/day), riboflavin (150 mg/day),
thiamin (150 mg/day), pyridoxin (200 mg/day), co-enzyme
Q (300 mg/day) and L-carnitine (1200 mg/day). Liver bi-
opsy was performed via laparoscopy in ambulatory setting.
During the next months, episodes with decreased aware-
ness occurred more frequently. When seen ambulatory at
the child neurology department, she was stuporous with
ptosis of the eyelids bilaterally and severe generalized
amyotrophy. No hepatomegaly neither signs of pyramidal
tract involvement were found. Her neurological condition
further deteriorated. Transaminases were measured re-
peatedly in blood and were either normal or only slightly
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increased. Ammonia in blood was also measured on
several occasions and was normal. She passed away at
home at the age of 6 ½ year.
Light microscopy, cytochemical analysis and electron
microscopy
The presence of Ki67 positive nuclei are proof of paren-
chymal cells proliferation, indicating regeneration after
cell death. Macrophages (Kupffer cells) contained large
PAS-diastase resistant inclusions, a consequence of par-
enchymal cell death (Fig. 1a). CK-7 positive small cells
were numerous throughout the parenchyma sometimes
forming abortive bile ducts (Fig. 1b). The latter are pro-
genitor cells proliferating after parenchymal cell death.
Lipid droplets were seen in some parenchymal cells.
Cytochrome c oxidase activity staining visualized a
mosaic pattern. Hepatocytes with strong mitochondrial
activity were adjacent to cells scarcely showing reaction
product (Fig. 1c-d).
Biochemical and molecular studies
Spectrophotometric analyses in liver tissue from the pro-
band showed significantly reduced activity of complex III
and low activities of complex I and IV (although still within
normal control range) (Table 1). BN-PAGE confirmed the
low activities of the complexes I, III and IV when compared
to those in liver tissue from a control and, in addition,
showed the presence of a catalytically active subcomplex of
complex V (Fig. 2). These results were suggestive of a defect
in replication, transcription or translation in the mitochon-
drial matrix. Mutations in mtDNA were excluded using
whole mtDNA sequencing.
Single person Whole Exome Sequencing (WES) was per-
formed and variants were filtered using a mitochondrial
gene panel based on the Human MitoCarta2.0. dataset [16].
As the great majority of mitochondrial diseases follows a
recessive mode of inheritance (after exclusion of mtDNA
alterations), only variants that were homozygous or com-
pound heterozygous were included. This filtering strategy
resulted in two compound heterozygous variants in the
WARS2 gene (NM_015836). The first variant (c.797delC,
p.Pro266ArgfsTer10) was a single nucleotide deletion caus-
ing a frameshift and premature stopcodon. The second
variant (c.938 A > T, p.Lys313Met) was a missense variant.
Both variants are rare in the healthy population, with
respectively a prevalence of 3/121.378 and 18/121.412 indi-
viduals [17]. Both variants have recently been reported in
compound heterozygous state in two subjects with WARS2
deficiency [10]. The second variant was also found in a
heterozygous state with another pathogenic variant in two
Fig. 1 Light and electron microscopy. Legend: (a) Cytokeratin 7 immunostaining is positive in numerous small cells throughout the liver
parenchyma. Some form abortive bile ducts. Their proliferation is proof of active liver regeneration. b Inclusions in macrophages indicate
phagocytosis of debris from damage. PAS after diastase digestion of glycogen; nuclear counterstain with hematoxylin. Parenchymal cells at the
right show large empty circular spaces, these are drops of dissolved fat. c Hepatocytes show mitochondria (rounded granules) with different
degrees of brown reaction product of cytochrome c oxidase activity. Nuclei are unstained. 2 μm plastic section, after postosmication. Obj. 100×,
oil immersion. d Mitochondrial mosaic observed by electron microscopy after reaction for cytochrome c oxidase activity. Mitochondria in the
hepatocyte at left show dark reaction product in their cristae. Three unstained round profiles in this cell are peroxisomes. Also seen are two large
fat globules that are partly dissolved. The other two hepatocytes have many mitochondria. Their cristae show little or no reaction product. The
dark granules in the cytoplasm of all three cells are glycogen rosettes × 7000
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other reported subjects [9, 10]. Variants were confirmed by
Sanger sequencing using variant-specific primers. Due to
the close proximity of the two variants, biallelic state could
be determined. A third primer pair was designed to confirm
compound heterozygosity. This primer pair resulted in a
PCR fragment containing both variants. As the position of
the missense variant was not affected by the deletion, both
variants were located on a different allele. Sanger sequen-
cing of DNA from the mother, revealed that she is a carrier
of the first variant (c.797delC, p.Pro266ArgfsTer10)
and does not carry the missense variant. DNA from
the father was not available for testing. Other genetic
causes such as defects in POLG, TWNK, mt- tRNALeu
and mt- tRNALys were checked using the WES data
and sequencing of the whole mt-DNA and chromosomal
abnormalities were not detected.
Western blot analysis
Western blot analysis for WARS2 was performed in liver
tissue from the proband and controls. Extracts were loaded
in duplicate on the same gel and transferred to a nitrocellu-
lose membrane. One part of the nitrocellulose membrane
was incubated with WARS2 antibody and the second part
with a cocktail of antibodies against subunits of the five
OXPHOS complexes. After incubation with WARS2 anti-
body, a prominent band at approximately 90 kDa was seen
in both controls. This band was clearly decreased in the
proband when compared to controls (Fig. 3). WARS2 pro-
tein has a calculated molecular mass of around 40 kDa.
The signal seen at 90 kDa was originating from the WARS2
homodimer [18]. The membrane was re-probed with a
VDAC-1 antibody to check for equal loading (Fig. 3). The
ratio of WARS2 signal over VDAC-1 signal shows an un-
equivocally decrease of the dimeric WARS2 protein in liver
tissue from the proband.
Results from incubation with a cocktail of five antibodies
(one against each of the five complexes) correlated with the
results obtained by BN-PAGE. The intensity of the bands
corresponding to complex I (NDFUB8) and complex IV
(COX2) were decreased. The band corresponding to the
complex II SDHB subunit was more intense in the pro-
band. An increased signal of the complex V alpha subunit
(54 kDa) was seen, which can be explained by the fact that
following denaturing conditions, the complex V alpha signal
is the combined signal of alpha subunits derived from the
holocomplex and from the subcomplexes of complex V
(data not shown).
Discussion
Here, we report on a 6-year-old child with WARS2 defi-
ciency. The proposita had presented at young age with
developmental delay, motor weakness and intellectual
disability. Her condition remained stable for several
years until she presented for the first time with seizures
Table 1 OXPHOS activities in liver homogenate from the
proband measured by spectrophotometric analysis
OXPHOS COMPLEXES Activity (Control range) Ratio/CS Z- score
Complex I 12 (9–49) 0.50 −1.65
Complex II 135 (52–202) 0.98 −0.89
Complex II + III 61 (18–70) 0.82 0.16
Complex III 52 (42–123) 0.79 −2.33
Complex IV 60 (31–174) 0.82 −1.85
Citrate synthase 148 (50–122) – –
Legend: Activities are shown as nmol/min/mg protein. The control range
(n = 30) is shown as (P5-P95). The ratios of the OXPHOS complexes over
citrate synthase (Ratio/CS) after logarithmic transformation are calculated, with
their respective Z-score. Z-scores lower than −1.96 are significantly different
(P < 0.05) from the result in control samples and are indicative of a significantly
decreased OXPHOS activity (shown in bold)
Fig. 2 BN-PAGE followed by in-gel activity staining. Legend: In-gel
activity staining of complex I, II, III, IV and V in liver tissue from the
proband compared to a control revealed lower activity of complex I,
III and IV in the proband. A catalytically active subcomplex of complex
V was seen in the proband
Fig. 3 Immunoblotting of WARS2 and VDAC-1 in liver. Legend:
Western blotting using antibodies against WARS2 and VDAC-1 in
mitochondrial liver extracts from the proband and controls. C: controls
and S: subject (proband)
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at the age of six years and a treatment with sodium
valproate was initiated. During the next month, her
clinical condition deteriorated rapidly and ultimately she
developed acute liver failure and severe encephalopathy.
Sodium valproate was stopped but nevertheless she
became progressively more unconscious and died half a
year later.
WARS2 deficient subjects were only very recently re-
ported in the literature. Musante et al. described the first
two WARS2 deficient siblings in 2017. These two girls, 17
and 16 years old, had developmental delay (IQ 41–46),
athetosis, speech impairment, motor weakness and
unbalanced gait. [7]. Another WARS2 deficient male who
was reported by Theissen et al. (2017) had developmental
delay, seizures starting at the age of six months and severe
language disability. At 24 years of age the neuromuscular
phenotype included generalized amyotrophy, spastic
quadriplegia, axial hypotonia, dysmetria, tremor and bilat-
eral horizontal nystagmus. He died at age 24 years [9]. Six
subjects with WARS2 deficiency were described by Wort-
mann et al. (2017). In three neonates overwhelming
hyperlactacidemia was documented and fatal outcome oc-
curred in early infancy. The fourth subject in this cohort
presented at four months of age with hypotonia, severe
cognitive and motor delay, cardiomyopathy and retinitis
pigmentosa. He died at the age of three years. The two
remaining subjects in this series presented with severe
cognitive and motor delay, one at age 13 months and the
other at 18 months. One of them had dystonia and the
other ataxia, nystagmus and optic atrophy. Both were alive
at, respectively, three years and ten years of age [10]. More
recently, Burke et al. (2017) reported on a subject with a
phenotype dominated by Parkinson-like signs. Develop-
ment was normal until the age of one year, when a left leg
tremor was first noticed. At 18 months of age, the tremor
had become apparent also on the right side and in the
upper extremities as well, along with intermittent dystonic
posturing of all extremities. Treatment with Levodopa
resulted in a stable period of 3–5 years with normal
development regarding acquisition of motor, language
and social milestones. Thereafter he began showing
signs of more advanced Parkinson disease and neck
dystonia [11].
Based on the clinical data of previously reported
subjects, three different clinical phenotypes can be
discerned, i.e. (a) a severe neonatal phenotype with
overwhelming hyperlactacidemia and fatal outcome at very
young age, (b) a more protracted course with early onset
developmental delay, motor weakness, extra-pyramidal
signs, with or without epilepsy, and (c) a phenotype
characterized by normal early development and
Parkinson-like symptoms starting around the age of
one year. The phenotype of the subject reported here fits
into the second phenotype (protracted course, early onset
developmental delay, motor weakness, extra-pyramidal
signs, epilepsy). She differs, however, from previously
reported subjects as she developed acute onset liver
failure. The hypothesis is that treatment with valproate
has induced or triggered a severe hepatopathy. No other
WARS2 deficient subjects with severe liver failure were
reported previously. One subject, reported by Wortmann
et al. was found to have hepatosplenomegaly which was
attributed to a CMV infection. Later, liver function tests
normalized in this subject [10]. An overview of the
WARS2 deficient subjects is shown in Table 2.
Sodium valproate is known to have a potential toxic
effect on mitochondrial functioning and is contraindi-
cated whenever a mitochondrial defect is suspected in a
subject. The pathogenesis of valproate toxicity is insuf-
ficiently understood. Valproate has been shown to
inhibit the activity of the complexes I and IV. It inhibits
oxygen consumption and adenosine triphosphate
synthesis and sequestrates coenzyme A. It can disturb
the structural organization of the inner mitochondrial
membrane. Depletion of hepatic cytochrome aa3 and
inhibition of the mitochondrial beta-oxidation was
documented [19, 20]. In most instances, the acute onset
of liver failure occurs shortly after sodium valproate
was initiated. Some of the affected subjects recover
after discontinuation of the valproate treatment while
in others the condition deteriorates further towards a
fatal outcome. Most of the valproate induced hepatopathy
subjects reported in the literature were carriers of patho-
genic mutations in POLG [21–26]. Valproate toxicity was
also documented in subjects with pathogenic mutations in
TWNK [27]. It can aggravate epilepsy due to MELAS in
subjects with the A3243G mutation in the mitochondrial
DNA [28, 29] and can cause secondary carnitine defi-
ciency in subjects with MERRF [30]. Fatal liver toxicity
was also reported in a subject with CPEO (Chronic
Progressive External Ophthalmoplegia) [31] and in several
subjects with Alpers syndrome without genetic
diagnosis [32, 33]. Spectrophotometric analysis in liver
of most of the subjects showed the combined deficiency
of complexes I, III and IV [25]. Sodium valproate can
trigger a latent congenital liver disease that would other-
wise have remained subclinical or would have manifested
later in life.
In the proband, spectrophotometrical analysis and
BN-PAGE in a liver biopsy specimen showed a deficient
activity of complex III and low normal activities of the
complexes I and IV. Complex V has two subunits that
are encoded by the mtDNA. In case these subunits are
not synthesized in the mitochondrial matrix, the rotor
of the complex V (F1) can detach from the holo-complex,
which can be detected as a smaller sub-complex in the
BN-PAGE gel. As the ATP synthase activity of complex V
is located in the alpha-subunit in the rotor, the presence
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of a sub-complex can be visualized in the BN-PAGE gel
using the ATP-ase staining [34]. The presence of a
subcomplex of complex V in our subject was therefore
suggestive of an intramitochondrial protein synthesis
defect. In earlier reported WARS2 deficient subjects,
biochemical analysis in liver has not been performed.
Immunohistochemical staining of OXPHOS enzymes in
the liver of one subject reported by Wortmann et al.
demonstrated severely reduced quantity of the complexes
I and IV. Remarkably this subject did not have any clinical
nor biochemical sign of liver failure. Immunohistochemical
staining in his skeletal muscle was normal. OXPHOS
activity measurements in skeletal muscle from four other
subjects with WARS2 deficiency revealed mildly deficient
enzymes in two of them [10, 11]. Activity testing in
cultured skin fibroblasts was normal in all tested subjects
in this series.
In the subject reported here, microscopic examination
of liver showed a mosaic pattern after activity staining of
cytochrome c oxidase. Hepatocytes with strong mito-
chondrial activity were found adjacent to cells that
showed scarce or no reaction product (Fig. 1c-d). Mito-
chondrial mosaic staining for cytochrome c oxidase in
liver has previously been reported in six subjects: (i) one
with Alpers syndrome caused by pathogenic mutations
in POLG, (ii) one with Pearson disease, (iii) in another
subject with POLG deficiency [14], (iv) in an infant with
encephalopathy and cholestatic giant cell hepatitis, (v) in
Table 2 Clinical and molecular data of reported WARS2 deficient subjects
Subject Publication Gender Age at onset Age at publication Clinical findings Molecular findings
F2-V:7
[7]
F ND 17 years Long philtrum, ataxia, athetosis, aggressive
behaviour
Trp13Gly Ser109Alafs*15
F2-V:8
[7]
F ND 16 years Long philtrum, ataxia, athetosis, aggressive
behaviour
Trp13Gly Ser109Alafs*15
[9] M Neonatal 24 years (deceased) Severe infantile onset leukoencephalopathy,
spastic quadriplegia, hypoglycemia (neonatal),
epilepsy
Leu100del
Lys313Met
F1, I1
[10]
F Neonatal 23 days (deceased) Fatal lactic acidosis Lys31_Gln116del
Val349Leu
F2, I2
[10]
M Neonatal 3.5 years (deceased) Lactic acidosis, epilepsy, hypoglycaemia (neonatal) Pro266Argfs*10
Lys313Met
F2, I3
[10]
M Neonatal 1.5 years (deceased) Lactic acidosis, epilepsy, hypoglycaemia (neonatal) Pro266Argfs*10
Lys313Met
F3, I4
[10]
F 4 months 3 years (deceased) Epilepsy, muscular hypotonia, cardiomyopathy,
retinitis pigmentosa
His77Gln
Glu352Lys
F4, I5
[10]
M 13 months 3 years Dystonia, suspected epilepsy Val178Leu
(homozygous)
F5, I6
[10]
F 18 months 10 years Ataxia, nystagmus Gly45Val
Lys313Met
[11] M 1 year 17 years Parkinson-like symptoms, dystonia Trp13Gly
Ser228Trp
Proband F Before 6 months 6.5 years (deceased) Epilepsy, ptosis, hypoglycaemia, valproate
induced hepatotoxicity
Pro266Argfs*10
Lys313Met
Fig. 4 Localization of the 12 reported variants in WARS2 (NM_015836)
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a subject with fatal infantile hepatic failure due to
mutations in POLG [26, 35], and (vi) in a subject with
MEGDEL syndrome [36].
A defect in a nuclear encoded gene was suspected in the
proposita as a combined defect of OXPHOS complexes
involving the complexes I, III and IV was seen in liver,
together with the presence of a subcomplex of complex V
and the normal entire mtDNA sequencing. Single person
WES was performed in order to pinpoint the underlying
molecular defect. Two variants were found in WARS2.
One was a frameshift mutation (c.797delC, p.Pro266Argf-
sTer10), the other a missense mutation (c.938 A > T, p.
Lys313Met). Both mutations are located in exon 6, the last
exon of WARS2 (NM_015836) (Fig. 4). Twelve different
pathogenic mutations in WARS2 have been reported so
far. The identical compound heterozygous mutant geno-
type (p.Pro266ArgfsTer10/ p.Lys313Met) was found in the
two subjects with severe neonatal expression reported by
Wortmann et al. (Table 2). The third subject with neonatal
phenotype in the series reported by the same group was
compound heterozygous for p.Lys31_Gln116del and
Val349Leu [10]. The p.Lys313Met missense mutation is
the most frequently detected pathogenic mutation in
WARS2, at least in the European population, as it was
detected in five of the eleven reported subjects (including
the one reported here). Of the twelve documented
mutations, most of them were situated in exon six (5/12)
or in exon two (5/12). Nine of the twelve pathogenic
mutations were missense mutations and two of the twelve
frameshift mutations (Fig. 4).
A wide variety of brain MRI abnormalities were found
in the WARS2 deficient subjects. In the subject reported
by Theissen et al. (2017), a delay of myelination, diffuse
cerebral atrophy and moderate symmetric ventriculome-
galy was described [9]. Also, four of the subjects reported
by Wortmann et al. (2017) were found to have MRI
abnormalities in the brain. In one, absent myelinisation of
the white matter was seen, in another white matter edema
and frontal atrophy, in the third hypoxemic-ischemic basal
ganglia lesions and in the fourth cerebral and cerebellar
atrophy [10]. In the subject reported by Burke et al. (2017)
progressive generalized brain atrophy but no dysmyelina-
tion nor leukoencephalopathy or abnormalities of the
basal ganglia were seen [11]. Cerebral MRI in the proband
also showed atrophy most prominent in the frontal
regions and, in addition, atrophy of the vermis cerebelli,
brainstem and cerebellar peduncles.
Conclusion
In conclusion, we broaden the clinical spectrum of WARS2
deficiency and report for the first time a severe hepatopathy
associated with valproate treatment in a subject with
WARS2 deficiency. Interestingly, the proband was initially
considered as having a non-specific, non-progressive
encephalopathy, and it was only when she developed hepa-
topathy after valproate treatment was started that the diag-
nosis of a mitochondrial defect was made. This report
shows that one should be cautious when starting valproate
treatment, even when a mitochondrial defect is not
suspected and POLG deficiency is excluded. More
observations are needed to confirm that WARS2 deficiency
can be added to the list of mitochondrial defects associated
with valproate-induced hepatopathy. Apparently, patho-
genic mutations in the nuclear genes POLG, TWNK and
WARS2, and in the mitochondrial genes tRNALeu and
tRNALys, all affecting intramitochondrial transcription and/
or translation, have been associated with valproate-induced
acute liver failure.
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